R2R BiofluidicsProject ID: 646260
Large scale micro-and nanofabrication technologies for bioanalytical devices based on R2R imprinting
Gesamtkosten:EUR 7 929 411
EU-Beitrag:EUR 6 421 672,57
Aufruf zur Vorschlagseinreichung:H2020-NMP-PILOTS-2014See other projects for this call
Finanzierungsprogramm:IA - Innovation action
Roll-to-roll (R2R) technologies are mature core processes in manufacturing lines for graphical printing industry. In several other areas (e.g. electronics or optics) R2R techniques are emerging, being expected to notably lower the unit prices of flexible devices.
In particular, recently developed roller-based nanoimprinting methods enable unrivalled throughput and productivity for precise fabrication of micro- and nanoscale patterns.
Areas that will benefit strongly from adopting such R2R nanoimprinting technologies are microfluidics and lab-on-chip products for diagnostics, drug discovery and food control. Such devices require combined printing of micro- and nanostructures and large quantities at low unit costs.
The project R2R Biofluidics aims on the development of a complete process chain for first-time realization of production lines for two selected bioanalytical lab-on-chip devices based on high-throughput R2R nanoimprinting in combination with complementary printing and manufacturing technologies.
Two types of demonstrators will be fabricated targeting application areas, which would clearly benefit from technology advancement in high volume manufacturing, show large potential for commercial exploitation and adopt current standard formats (microtiter plate and microscope slides).
Demonstrator 1 will represent an in-vitro diagnostic (IVD) chip suitable for point-of-care applications, showing improved sensitivity thanks to imprinted nanoscale optical structures and microfluidic channels. R2R fabrication will further greatly reduce production costs and increase manufacturing capacity with respect to currently used products.
Demonstrator 2 will provide a device for improved neuron based high-throughput screening assays in drug development. It will consist of nano– to microstructured, interconnected channels in combination with dedicated biofunctionalized surfaces for alignment and controlled growth of neurons.
EU-Beitrag: EUR 1 898 851,25
EU-Beitrag: EUR 248 850
EU-Beitrag: EUR 399 827,50
EU-Beitrag: EUR 216 300
EU-Beitrag: EUR 1 253 021
DI ERICH THALLNER STRASSE 1
4782 ST FLORIAN AM INN
EU-Beitrag: EUR 369 641,12
4261 RAINBACH IM MUHLKREIS
EU-Beitrag: EUR 587 853,70
GREGERSENSVEJ 6 H HOJE TAASTR
EU-Beitrag: EUR 295 515,50
PARQUE TECNOLOGICO DE BIZKAIA 502-1
EU-Beitrag: EUR 546 875
Koepenicker Strasse 325
EU-Beitrag: EUR 604 937,50
PARQUE CIENTIFICO Y TECNOLOGICO DE BIZKAIA C GELDO EDIFICIO 700
48160 DERIO BIZKAIA